Dyne Therapeutics reported a third-quarter net loss of $193.6 million, or $1.06 per basic and diluted share, compared to a $108.0 million loss in the prior-year period. Research and development expenses rose to $161.7 million from $97.2 million due to increased manufacturing for z-rostudirsen and higher clinical trial costs for Phase 3 FORZETTO and HARMONIA trials. General and administrative expenses increased to $35.3 million from $16.7 million, driven by preparations for the potential U.S. launch of z-rostudirsen. The company ended the quarter with $1.134 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations into Q2 2028. Dyne Therapeutics is a clinical-stage biopharmaceutical company focused on developing genetically driven neuromuscular disease therapies.
